Abstract
Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibitor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor therapy.
Original language | English |
---|---|
Article number | 3157 |
Pages (from-to) | 3157 |
Journal | Nature Communications |
Volume | 11 |
Issue number | 1 |
DOIs | |
Publication status | Published - 22 Jun 2020 |
Funding
We thank A. Bardelli (Torino, Italy) for gift of cell lines, the facilities of The Netherlands Cancer Institute: Mouse Clinic–Intervention Unice (Natalie Proost, Bjorn Siteur, Bas van Gerwen, Charlotte Baak, Renske Grimmerink, Rebecca Theeuwsen and Marieke van de Ven), Robotics and Screening Center (Ben Morris and Roderick Bei-jersbergen), Clinical Pharmacology (Levi Buil and Artur Burylo), Experimental Animal Pathology, Flow Cytometry and Sequencing. We also thank Richard Marais for discussions. This work was supported by a grant from the Dutch Cancer Society through the Oncode Institute. Al.V. was supported by the Fondo de Investigaciones Sanitarias, FIS (PI16-01898, and by the Spanish Association Against Cancer, AECC (CGB14142035THOM) and Ideas Semilla project (IDEAS098VILL-IDEAS16) and Generalitat de Catalunya (2014SGR364). L.F. received a European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie, grant agreement number 799850. E.N. was funded by Instituto Carlos III through the project PI18/00920. We thank CERCA Program/Generalitat de Catalunya for their institutional support and grant 2017SGR448.
Funders | Funder number |
---|---|
Dutch Cancer Society | |
Fondo de Investigaciones Sanitarias | PI16-01898 |
Marie Sklodowska-Curie | |
Oncode Institute | |
Spanish Association Against Cancer | |
Albert Einstein Cancer Center | IDEAS098VILL-IDEAS16, CGB14142035THOM |
Horizon 2020 Framework Programme | 799850 |
Generalitat de Catalunya | 2014SGR364 |
Instituto de Salud Carlos III | PI18/00920 |